Printer Friendly

ROBERTS PHARMACEUTICAL ACQUIRES COMHIST ANTI-ALLERGY PRESCRIPTION PHARMACEUTICAL PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS

 EATONTOWN, N.J., Nov. 24 ~PRNewswire~ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it purchased the U.S. rights to COMHIST(R) LA and COMHIST(R), an anti-allergy prescription pharmaceutical product line from Procter & Gamble Pharmaceuticals of Norwich, N.Y. COMHIST is a decongestant~anti- histamine combination product used for the relief of rhinorrhea and congestion associated with seasonal and~or perennial allergic rhinitis (hayfever). The line consists of a sustained-release capsule formulation and an immediate release tablet. Specific terms of the agreement were not disclosed; however it is expected that the transaction will be completed on a cash basis.
 "The acquisition of the COMHIST line of anti-allergy products represents another important commitment Roberts is making in the market for respiratory drugs," stated Dr. Robert A. Vukovich, Roberts CEO and chairman. "Together with our recent acquisition of the cough~cold brand, NUCOFED(R) from SmithKline Beecham, the acquisition of the COMHIST line will help us gain an important foothold in respiratory care, a large market in which Roberts has significant interest," he continued. Roberts currently is developing a new bronchodilator respiratory drug, MAXIVENT(R) (doxofylline), which is in Phase III clinical trials in the United States.
 "COMHIST is an excellent drug, but is no longer a fit with our strategic plan," stated G. Gilbert Cloyd, vice-president pharmaceuticals and vice-president, research and development, health care products.
 Procter & Gamble had sales of $29.3 billion during fiscal 1991-92. P&G makes and markets a wide range of products for consumer and industry, including prescription health care and over-the-counter products. Procter & Gamble Pharmaceuticals is responsible for the company's growing prescription drug business.
 Roberts Pharmaceuticals is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and non-prescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough~cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 11~24~92
 ~CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182~
 (RPCX)


CO: Roberts Pharmaceutical Corporation; Procter & Gamble
 Pharmaceuticals ST: New Jersey IN: MTC SU: TNM


LR-PS -- NY022 -- 0973 11~24~92 10:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 24, 1992
Words:387
Previous Article:CANAVERAL INTERNATIONAL ANNOUNCES ACQUISITION AGREEMENT
Next Article:SOUTHERN CALIFORNIA EDISON CO. SENIOR DEBT, PREFERRED LOWERED TO 'A+' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES SIGNING OF MERGER AGREEMENT WITH HAUCK PHARMACEUTICALS
ROBERTS PHARMACEUTICALS ANNOUNCES ACQUISITION OF THREE MARKETED U.K. AND IRISH BRANDS FROM BOEHRINGER INGELHEIM
ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS
ROBERTS PHARMACEUTICALS COMPLETES ACQUISITION OF HAUCK PHARMACEUTICALS
PROCTER & GAMBLE TO ACQUIRE ROEHM PHARMA
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES FOUR PRESCRIPTION PRODUCTS FROM SEARLE CANADA INC.
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES PRODUCT ACQUISITION AGREEMENT WITH BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES PRODUCT ACQUISITION FROM GLAXO CANADA INC.
ROBERTS PHARMACEUTICAL COMPLETES UNITED KINGDOM PRODUCT ACQUISITION FROM PROCTER & GAMBLE
DURA PHARMACEUTICALS ANNOUNCES ACQUISITION OF ENTEX(R) PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters